Autophagy enhancement via Curcumin-Rapamycin microdosing combination
MedicOath Autonomous Discovery Engine
Zenodo (CERN European Organization for Nuclear Research) April 28, 2026 DOI: 10.5281/zenodo.19833227 via OpenAlex
Summary
AI-generated from the abstractA combination of ultra-low dose rapamycin (0.1 mg weekly) and a bioavailable curcumin formulation increases the movement of TFEB into the nucleus and activates the ULK1-Beclin1-ATG5 autophagy machinery. This clears accumulated nucleic acids and damaged organelles that otherwise trigger interferon responses in AGS cells.
Study at a glance
| Characteristics | Preclinical study Peer reviewed |
|---|---|
| Population | AGS cells |
| Interventions | rapamycin curcumin |
| Dose | 0.1 mg weekly rapamycin |
| Keywords | Autophagy Tfeb Curcumin Organelle Nucleic acid |
| Key finding | Ultra-low dose rapamycin combined with bioavailable curcumin enhances TFEB nuclear translocation and autophagy to clear nucleic acids and damaged organelles, reducing interferon responses in AGS cells. |
Abstract
Ultra-low dose rapamycin (0.1mg weekly) combined with bioavailable curcumin formulation enhances TFEB nuclear translocation and ULK1-Beclin1-ATG5 autophagy machinery to clear accumulated nucleic acids and damaged organelles triggering interferon responses in AGS.